Thrombolytic therapy for coronary occlusion.
Thompson
P L
PL
University of Western Australia, Sir Charles Gairdner Hospital, Perth.
D016255:Anistreplase / Q000009:adverse effects / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001315:Australia; D002543:Cerebral Hemorrhage / Q000139:chemically induced; D002986:Clinical Trials as Topic; D016527:Drug Costs; D004359:Drug Therapy, Combination; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy*; D013300:Streptokinase / Q000009:adverse effects / Q000627:therapeutic use; D015912:Thrombolytic Therapy / Q000009:adverse effects; D010959:Tissue Plasminogen Activator / Q000009:adverse effects / Q000627:therapeutic use
D000925:Anticoagulants; D016255:Anistreplase; D013300:Streptokinase; D010959:Tissue Plasminogen Activator